Last reviewed 2026-04-23 · How we verify

LNG-IUS (BAY 86-5028)

LNG-IUS is a levonorgestrel-releasing intrauterine system that provides long-acting reversible contraception by releasing a synthetic progestin directly into the uterus.

LNG-IUS is a levonorgestrel-releasing intrauterine system that provides long-acting reversible contraception by releasing a synthetic progestin directly into the uterus. Used for Contraception (long-acting reversible), Heavy menstrual bleeding (off-label/secondary indication).

At a glance

Mechanism of action

The device releases levonorgestrel (a synthetic progestin) in small amounts directly into the uterine cavity over an extended period. This creates a local contraceptive effect through multiple mechanisms: thickening cervical mucus to impede sperm transport, altering the endometrium to prevent implantation, and suppressing ovulation in some cycles. The localized delivery minimizes systemic hormone exposure compared to oral contraceptives.

Approved indications

• Contraception (long-acting reversible)
• Heavy menstrual bleeding (off-label/secondary indication)

Common side effects

• Irregular bleeding or amenorrhea
• Abdominal/pelvic pain
• Headache
• Breast tenderness
• Device expulsion
• Perforation (rare)

Key clinical trials

• LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• LNG-IUS (BAY 86-5028) CI brief — competitive landscape report
• LNG-IUS (BAY 86-5028) updates RSS · CI watch RSS
• Bayer portfolio CI